GlaxoSmithKline PLC
15 March 2001
Director's Interests
I give below details of changes in interests in the Ordinary Shares of
GlaxoSmithKline plc in respect of the under-mentioned directors:-
Mr John Exercised a nominal cost option (£1.00) on 12 March 2001 to acquire
D 25,120 shares in the Company, which had vested under the Glaxo Wellcome
Coombe 1998 Long Term Incentive Plan. Mr Coombe subsequently sold 10,069 of
the shares so acquired at a price of £18.45 per share to pay the
resultant tax liability and to meet the costs arising from the sale.
Sold 15,000 Ordinary Shares in the Company on 13 March 2001 at a price
of £18.12 per share.
Sir Disposal of 10,000 Ordinary Shares in the Company on 13 March 2001 by
Richard way of gift.
Sykes
The Company was advised of these transactions on the 14 March 2001.
SM Bicknell
Company Secretary
15 March 2001
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.